1. Home
  2. FUSB vs SCLX Comparison

FUSB vs SCLX Comparison

Compare FUSB & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

HOLD

Current Price

$15.42

Market Cap

86.5M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$8.09

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
SCLX
Founded
1952
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.5M
90.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FUSB
SCLX
Price
$15.42
$8.09
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
7.1K
41.4K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
1.84%
N/A
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
$24.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.47
$0.18
52 Week High
$15.99
$34.27

Technical Indicators

Market Signals
Indicator
FUSB
SCLX
Relative Strength Index (RSI) 57.40 37.66
Support Level $13.54 $7.82
Resistance Level $15.99 $12.30
Average True Range (ATR) 0.32 0.63
MACD -0.06 0.19
Stochastic Oscillator 81.96 28.25

Price Performance

Historical Comparison
FUSB
SCLX

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: